Cancer Pain Clinical Trial
Official title:
Injection of 35kDa Hyaluronan Fragment Alleviates Pain Associated With Radiotherapy for Treatment of Colorectal and Rectal Cancer
HA35 (Bioactive HA or B-HA or HA35) have good tissue permeability (B-HA injection, Ministry of Health, Registration number L20200708MP07707). HA35 might not lose HA's bioactivities of binding to a variety of hyaluronan's binding proteins or receptors, including the analgesic and anticancer effects of hyaluronan, therefore being named bioactive HA or B-HA (10) (B-HA injection, Ministry of Health, Registration number L20200708MP07707).
The previous study has shown that naked mole rat who has high tissue content of hyaluronan and its fragments is insensitive to pain. The previous study has also shown that hyaluronan modulates pain-regulated TRPV1 channel opening, reducing peripheral nociceptor activity and pain. The previous study has again shown that local injection of 35kDa hyaluronan fragment HA35 is effective in treating inflammatory and neuropathic pain. This study employs freshly made HA35 injection for treatment of pain associated with radiotherapy for treatment of colorectal and rectal cancer. A numerical rating scale from 0 to 10 was used to assess the pain after 1 hour, 3 hours, 24 hours, 48 hours and 72 hours of the injection. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03375515 -
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
|
Phase 3 | |
| Recruiting |
NCT03431922 -
Endovascular Denervation in Patients With Cancer Pain
|
N/A | |
| Not yet recruiting |
NCT05265052 -
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
|
Phase 2 | |
| Withdrawn |
NCT05325164 -
Methadone for 'Adenocarcinopathic' Pain Treatment
|
Phase 3 | |
| Completed |
NCT02664987 -
Analgesic Treatment for Cancer Pain in South East Asia
|
N/A | |
| Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
| Active, not recruiting |
NCT04095234 -
Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)
|
Phase 2 | |
| Recruiting |
NCT05800834 -
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds
|
Phase 2 | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Completed |
NCT02609828 -
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
|
Phase 3 | |
| Completed |
NCT03331055 -
PENS or TENS for Pain in Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT05506878 -
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
|
N/A | |
| Completed |
NCT00766831 -
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
|
Phase 4 | |
| Recruiting |
NCT05051735 -
PARASTOP - Paracetamol With Strong Opioids
|
Phase 3 | |
| Not yet recruiting |
NCT05348174 -
Randomized Controlled Trial of Virtual Reality Assisted Guided Imagery (VRAGI) for Pain in Advanced Cancer Patients.
|
N/A | |
| Completed |
NCT05209906 -
An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain
|
||
| Completed |
NCT03031938 -
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
|
Phase 3 | |
| Not yet recruiting |
NCT05594459 -
Early Treatment With Invasive Technique in Cancer Pain Management
|
N/A | |
| Withdrawn |
NCT04666623 -
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
|
Phase 2 | |
| Not yet recruiting |
NCT05049811 -
Effects of Mobile Medicine on Cancer Patients
|
N/A |